Data from Phase III KEYNOTE-564 study of adjuvant pembrolizumab in renal cell carcinoma (RCC) presented at conference

In patients with RCC at intermediate-high or high risk of recurrence following nephrectomy (n=994), adjuvant pembrolizumab was associated with an improvement in the primary endpoint of disease-free survival v placebo (median not yet achieved; HR 0.68; 95% CI 0.53-0.87; p=0.001).

Source:

Biospace Inc.